Mirum Adds To Rare Liver Disease Portfolio With Bluejay Acquisition

 
• By Joseph Haas
  
Acquisition deal
Acquiring Bluejay adds another rare liver disease asset to Mirum's portfolio (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business